Methods for treating late-stage small cell lung cancer by administering a human anti-PD-L1 antibody, an etoposide and a platinum-based therapeutic
US12012453B2 · kind B2 · utility
0Cited by
3References
48Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 4, 2020 |
| Grant date | Jun 18, 2024 |
| Priority date | — |
| Expiry date | Dec 8, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods for treating extensive-stage small-cell lung cancer (ES-SCLC) with an antibody that inhibits PD1/PD-L1 activity in combination with etoposide and a platinum-based therapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.